Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

1. [Sulfasalazine relieves cholestatic liver injury by activating peroxisome proliferator-activated receptor-α].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
   Article
2. Current Therapeutics in Primary Sclerosing Cholangitis.Journal of clinical and translational hepatology · 2023
   Review
3. The microbiota and the gut-liver axis in primary sclerosing cholangitis.Nature reviews. Gastroenterology & hepatology · 2023
   Review
4. Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker.Scientific reports · 2018
   Article
5. Autoimmune liver disease and the enteric microbiome.AIMS microbiology · 2018
   Review
6. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.The Cochrane database of systematic reviews · 2017
   Review
7. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.Scandinavian journal of gastroenterology · 2014
   Review
8. Role of the microbiota and antibiotics in primary sclerosing cholangitis.BioMed research international · 2013
   Review
9. The medical management of primary sclerosing cholangitis.Medscape journal of medicine · 2008
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as